<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
    December 2, 2012

    Bedaquiline backed by FDA panel

    FDA Advisory Committee Recommends Accelerated Approval of JNJ's Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline

     

    This week while attending the Partnering for Cures meeting in New York (http://www.partneringforcures.org/), Bedaquiline was backed by the FDA panel that has been reviewing it since late June. Hopefully, it will be approved by the FDA in due course, because then it becomes the first drug approved for tuberculosis in well over 40 years. This will be a potential success for Johnson and Johnson, the TB Alliance and everyone involved in funding it. While this is terrific news for patients, we need additional molecules in the pipeline, because elevated liver enzymes and QT prolongation were observed. One would assume that it was tested against the ion channel hERG and various nuclear receptors given the size, hydrophobicity, and other physicochemical properties that would alert experts who have studied these proteins and their relationship to QT prolongation and liver enzyme induction?

    Surprisingly, little mention of this panel decision was made at the meeting in New York, which is unfortunate because the background story behind it illustrates many of the aspects discussed at the meeting. For example Public Private Partnerships (J&J and TB Alliance), PDUFA, Philanthropy etc... Maybe next year it will be highlighted. While not likely to be a very profitable drug it will provide good visibility for J&J and help to bolster the image of a company and an industry that has taken a lot of setbacks in recent years.

    Let's hope it encourages other companies to collaborate to discover drugs for this disease that are faster acting and less toxic than current treatments and that it does not take another 40 years to get there.

    Sean Ekins Ph.D, D.Sc.
    VP, Science. CDD.


    This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registrationstructure activity relationshipchemical inventory, and electronic lab notebook capabilities!

    CDD Vault: Drug Discovery Informatics your whole project team will embrace!

    Other posts you might be interested in

    View All Posts
    CDD Blog
    2 min   April 22, 2024
    Recorded Presentations: CDD 20th Anniversary User Group Meeting
    Read More
    CDD Blog
    9 min   April 19, 2024
    Drug Discovery Industry Roundup with Barry Bunin — April 19, 2024
    Read More
    CDD Blog
    2 min   April 19, 2024
    CDD Appoints Yasushi Hamagashira as Head of Sales and Marketing for Japan
    Read More